For the first time in Canada, a patient in Toronto has achieved undetectable HIV levels without ongoing treatment, following an allogeneic bone marrow transplant performed in November 2021 to treat blood cancer.¹ The donor cells used in the transplant carried a rare genetic mutation that confers natural resistance to HIV infection. After stopping antiretroviral therapy (ART) in July 2025, the patient’s HIV has remained undetectable through April 2026.

Some may consider this a glimpse of an HIV “cure.” Others will note that this result rests upon a high-risk oncology procedure. For life insurance underwriters, the more pressing question is: what does this development change today—and what could it alter in the future?

This outcome was not the result of a widely applicable HIV intervention. Bone marrow transplantation is a complicated, high-acuity procedure with significant short- and long-term risks, generally reserved for specific malignant blood disorders. It is not a clinical pathway intended for the broader HIV population.

That said, the underlying biology is compelling. This case spotlights two research avenues likely to become increasingly important in coming years: (1) approaches for reducing or eradicating dormant viral reservoirs, and (2) methods to block viral entry, which are closely related to the donor-cell resistance observed here. If these innovations can be safely scaled and broadly implemented, they could profoundly reshape expectations for long-term morbidity and mortality among people living with HIV.

This is not a cure in practical underwriting terms. Remission achieved through transplantation remains rare, and is supported by only a handful of exceptional cases globally. Still, it signals credible scientific progress that may, over time, widen the pool of applicants living with HIV who qualify for life insurance, including living benefits—especially if future treatments deliver durable remission without the risks associated with transplantation. For now, underwriting decisions should remain grounded in current clinical realities, while staying flexible as scientific evidence continues to evolve. 

Munich Re is committed to maintaining a thorough understanding of medical advancements and research. We will actively monitor emerging trends, significant discoveries, and innovative treatments, ensuring that our underwriting expertise stays current with scientific progress and assisting clients in anticipating how evidence-based changes may influence future risk selection and pricing.